BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 2 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9 | -93.5% | 41,700 | -37.9% | 0.00% | – |
| Q2 2023 | $139 | -61.1% | 67,200 | -37.8% | 0.00% | – |
| Q1 2023 | $357 | +101.7% | 108,000 | 0.0% | 0.00% | – |
| Q4 2022 | $177 | -100.0% | 108,000 | 0.0% | 0.00% | – |
| Q3 2022 | $478,000 | +86.0% | 108,000 | +16.1% | 0.00% | – |
| Q2 2022 | $257,000 | -17.6% | 93,000 | 0.0% | 0.00% | – |
| Q1 2022 | $312,000 | -16.1% | 93,000 | 0.0% | 0.00% | – |
| Q4 2021 | $372,000 | +21.2% | 93,000 | 0.0% | 0.00% | – |
| Q3 2021 | $307,000 | -13.0% | 93,000 | 0.0% | 0.00% | – |
| Q2 2021 | $353,000 | -24.6% | 93,000 | -23.9% | 0.00% | – |
| Q1 2021 | $468,000 | +372.7% | 122,161 | +460.2% | 0.00% | – |
| Q4 2020 | $99,000 | -44.4% | 21,806 | +107.3% | 0.00% | – |
| Q3 2020 | $178,000 | – | 10,520 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| EAM Investors, LLC | 129,929 | $603,000 | 0.19% |
| ABNER HERRMAN & BROCK LLC | 56,050 | $260,000 | 0.06% |
| CFO4Life Group, LLC | 12,000 | $56,000 | 0.03% |
| Spark Investment Management LLC | 12,000 | $55,000 | 0.03% |
| Phoenix Holdings Ltd. | 118,533 | $534,000 | 0.03% |
| HighPoint Advisor Group LLC | 13,533 | $82,000 | 0.02% |
| GSA CAPITAL PARTNERS LLP | 12,500 | $58,000 | 0.02% |
| ETF MANAGERS GROUP, LLC | 66,197 | $299,000 | 0.01% |
| WINTON GROUP Ltd | 76,967 | $357,000 | 0.01% |
| IHT Wealth Management, LLC | 13,000 | $60,000 | 0.01% |